{"id":172164,"date":"2025-11-06T04:47:27","date_gmt":"2025-11-06T09:47:27","guid":{"rendered":"https:\/\/44.250.171.167\/?p=172164"},"modified":"2025-11-06T04:47:27","modified_gmt":"2025-11-06T09:47:27","slug":"aurobindo-pharma-q2-fy26-earnings-results","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-q2-fy26-earnings-results\/","title":{"rendered":"Aurobindo Pharma Q2 FY26 Earnings Results"},"content":{"rendered":"<p>Aurobindo Pharma Ltd, a leading pharmaceutical company focused on active pharmaceutical ingredients and generic pharmaceuticals, reported a steady Q2FY26 financial performance with revenues rising 6.3% year-on-year to \u20b98,286 crore. Consolidated net profit increased by 3.8% to \u20b9848 crore, reflecting resilience in key markets such as the US and Europe.<\/p>\n<h2><strong>Key Highlights:<\/strong><\/h2>\n<ul>\n<li><strong>Revenue Growth:<\/strong> Revenues for Q2FY26 rose to \u20b98,286 crore from \u20b97,796 crore in the prior year.<\/li>\n<li><strong><a href=\"https:\/\/www.bseindia.com\/stock-share-price\/aurobindo-pharma-ltd\/auropharma\/524804\/corp-announcements\/\" target=\"_blank\" rel=\"noopener\">Profit<\/a>:<\/strong> Net profit grew modestly to \u20b9848 crore from \u20b9817 crore.<\/li>\n<li><strong>EPS:<\/strong> Earnings per share increased 3.8% to \u20b914.48.<\/li>\n<li><strong>Market Performance:<\/strong> US formulations contributed 43.9% of revenues, growing 3.1%. European markets saw 17.8% growth, while growth markets increased 8.7%.<\/li>\n<li><strong>EBITDA and Margins:<\/strong> EBITDA increased 7.1% to \u20b91,678 crore, with a 20.3% margin.<\/li>\n<li><strong>R&amp;D:<\/strong> Continued focus on innovation with \u20b9414 crore spent on research and development.<\/li>\n<li><strong>Strategic Remarks:<\/strong> Management highlighted balanced growth and profitability with ongoing strategic initiatives on track.<\/li>\n<\/ul>\n<h2>Financial Highlights:<\/h2>\n<ul>\n<li>Revenues for the quarter rose 6.29% year on year to \u20b98,286 crore, up from \u20b97,796 crore.<\/li>\n<li>Total expenses increased by 6.05% to \u20b97,132 crore compared to \u20b96,725 crore last year.<\/li>\n<li>Consolidated net profit grew 3.79% to \u20b9848 crore, higher than \u20b9817 crore for the same quarter previously.<\/li>\n<li>Earnings per share increased by 3.80% to \u20b914.48 from \u20b913.95.<\/li>\n<\/ul>\n<p>The company continues to benefit from steady demand in key regulated markets including the US and Europe. Operational efficiencies and a diverse product portfolio have helped maintain profitability amid evolving industry dynamics.<\/p>\n<h2>Strategic Outlook:<\/h2>\n<p>Aurobindo Pharma is focused on leveraging its R&amp;D capabilities and market diversification to sustain growth. Its commitment to innovation, compliance, and expanding global footprints positions the company well for long-term value creation in the competitive pharmaceutical landscape.<\/p>\n<p>Explore the company\u2019s past earnings and latest concall transcripts, <a href=\"https:\/\/44.250.171.167\/symbol\/auropharma\/\">click here<\/a> to visit the AlphaStreet India News Channel.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-172165\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/auro.png\" alt=\"Q2 FY26\" width=\"1489\" height=\"1817\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/auro.png 1489w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/auro-246x300.png 246w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/auro-839x1024.png 839w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/auro-768x937.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/auro-1259x1536.png 1259w\" sizes=\"auto, (max-width: 1489px) 100vw, 1489px\" \/><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Aurobindo Pharma Ltd, a leading pharmaceutical company focused on active pharmaceutical ingredients and generic pharmaceuticals, reported a steady Q2FY26 financial performance with revenues rising 6.3% year-on-year to \u20b98,286 crore. Consolidated net profit increased by 3.8% to \u20b9848 crore, reflecting resilience in key markets such as the US and Europe. Key Highlights: Revenue Growth: Revenues for [&hellip;]<\/p>\n","protected":false},"author":1932,"featured_media":172165,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,392],"tags":[10162],"class_list":["post-172164","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infographics","category-earnings","tag-pharmaceutical"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/auro.png","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":142550,"url":"https:\/\/alphastreet.com\/india\/earnings-aurobindo-pharma-ltd-nseauropharma-q3fy23-results-out-total-income-rise-7-yoy\/","url_meta":{"origin":172164,"position":0},"title":"Earnings | Aurobindo Pharma Ltd. (NSE:AUROPHARMA): Q3FY23 Results Out; Total Income rise 7% YoY","author":"Divyansh_Kasana","date":"February 22, 2023","format":false,"excerpt":"Aurobindo Pharma Ltd. (NSE:AUROPHARMA) is a global pharmaceutical company headquartered in India. The company produces and sells a wide range of generic pharmaceutical products and active pharmaceutical ingredients (APIs) in over 150 countries. Aurobindo Pharma's portfolio includes antibiotics, anti-retrovirals, anti-inflammatory drugs, cardiovascular drugs, and more. The company operates manufacturing facilities\u2026","rel":"","context":"In &quot;Earnings&quot;","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":140759,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-limited-nse-auropharma-q3-fy23-results-out-total-income-rises-7-yoy\/","url_meta":{"origin":172164,"position":1},"title":"Aurobindo Pharma Limited (NSE: AUROPHARMA): Q3 FY23 Results Out; Total Income Rises 7% YoY","author":"Divyansh_Kasana","date":"February 9, 2023","format":false,"excerpt":"Aurobindo Pharma Limited (NSE: AUROPHARMA) is a pharmaceutical company based in Hyderabad, India. The company was founded in 1986 and has since grown to become one of the largest pharmaceutical companies in India, with a presence in over 150 countries. Aurobindo Pharma produces a wide range of generic and specialty\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/b7778d7c-e8b5-4ee8-8702-740018666b7d.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/b7778d7c-e8b5-4ee8-8702-740018666b7d.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/b7778d7c-e8b5-4ee8-8702-740018666b7d.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/b7778d7c-e8b5-4ee8-8702-740018666b7d.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/b7778d7c-e8b5-4ee8-8702-740018666b7d.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/b7778d7c-e8b5-4ee8-8702-740018666b7d.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169833,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-ltd-q1-fy26-earnings-results-revenue-up-4-net-profit-falls-10-yoy\/","url_meta":{"origin":172164,"position":2},"title":"Aurobindo Pharma Ltd Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 6, 2025","format":false,"excerpt":"Aurobindo Pharma Limited is a key player in the pharmaceutical industry. It manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services. The company supports global healthcare with a broad product portfolio that serves both developed and emerging markets. Financial Highlights In Q1 FY26, Aurobindo Pharma reported revenue\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AU.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AU.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AU.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AU.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AU.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AU.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":133199,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-limited-q1-fy-2023-research-tear-sheet\/","url_meta":{"origin":172164,"position":3},"title":"Aurobindo Pharma Limited Q1 FY 2023 Research Tear Sheet","author":"sreerupa","date":"August 15, 2022","format":false,"excerpt":"Stock Data Ticker: AUROPHARMA Exchange :NSE and BSE Industry: Automobile Price Performance Last 7 days\u00a0\u00a0\u00a0 4.36% YTD\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 -19.19% Last 12 months\u00a0\u00a0\u00a0\u00a0 -28.17% It will be beneficial to invest in the stocks of Aurobindo Pharma. The company enjoys a \u00a0healthy\u00a0ROE of\u00a021.49% ROE which is an\u00a0 important financial parameter. The company has\u2026","rel":"","context":"In &quot;Analysis&quot;","block_context":{"text":"Analysis","link":"https:\/\/alphastreet.com\/india\/category\/stock-analysis\/"},"img":{"alt_text":"Research Summary","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":172893,"url":"https:\/\/alphastreet.com\/india\/entero-healthcare-q2-fy26-earnings-results\/","url_meta":{"origin":172164,"position":4},"title":"Entero Healthcare Q2 FY26 Earnings Results","author":"Divyansh_Kasana","date":"December 3, 2025","format":false,"excerpt":"Entero Healthcare Solutions Ltd, incorporated in 2018 and engaged in distribution and marketing of pharmaceutical and surgical products with allied services, reported robust financial results for Q2FY26. Financial Highlights: Revenues increased 20.75% year-on-year to \u20b91,571 crore from \u20b91,301 crore. Total expenses rose 19.98% to \u20b91,531 crore from \u20b91,276 crore. Consolidated\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Q2 FY26","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/ENT.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/ENT.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/ENT.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/ENT.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/ENT.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/ENT.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":172285,"url":"https:\/\/alphastreet.com\/india\/divis-laboratories-q2-fy26-earnings-results\/","url_meta":{"origin":172164,"position":5},"title":"Divis Laboratories Q2 FY26 Earnings Results","author":"Divyansh_Kasana","date":"November 10, 2025","format":false,"excerpt":"Divis Laboratories Ltd, a leading manufacturer and exporter of APIs, intermediates, and nutraceutical ingredients, reported strong financial results for Q2FY26. Financial Highlights: Revenues increased 16.12% year on year to \u20b92,715 crore from \u20b92,338 crore. Total expenses went up 13.12% to \u20b91,948 crore from \u20b91,722 crore. Consolidated net profit surged 35.1%\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Q2 FY26","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/D.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/D.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/D.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/D.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/D.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/D.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/172164","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1932"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=172164"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/172164\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/172165"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=172164"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=172164"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=172164"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}